The Association of the British Pharmaceutical Industry (ABPI) has published new clinical testing guidelines. The new guidelines are intended to provide more suitable advice on dosages and patient selection in the administration of early-stage clinical trials. ABPI Director General Richard Barker stated that the, "Safety of volunteers for Phase 1 clinical trials is paramount, and this is at the heart of the revised guidelines,"
The guidelines have been produced in consultation with stakeholders, clinical experts and industry best practices.
For more information, please see: